{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T17:29:03Z","timestamp":1725730143645},"publisher-location":"Totowa, NJ","reference-count":69,"publisher":"Humana Press","isbn-type":[{"type":"print","value":"9781617371431"},{"type":"electronic","value":"9781592598175"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004]]},"DOI":"10.1007\/978-1-59259-817-5_10","type":"book-chapter","created":{"date-parts":[[2013,6,8]],"date-time":"2013-06-08T04:19:45Z","timestamp":1370665185000},"page":"183-203","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic Transplantation in Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"G\u00f6sta","family":"Gahrton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bensinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJM199501263320403","volume":"332","author":"RA Zittoun","year":"1995","unstructured":"Zittoun RA, Mandelli F, Willemze R, et al. for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematoloigche Maligne Dell\u2019Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332:217\u2013223.","journal-title":"N Engl J Med"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/sj.bmt.1700933","volume":"20","author":"F Rhee van","year":"1997","unstructured":"van Rhee F, Szydlo RM, Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20:553\u2013560.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR3","first-page":"405","volume":"22","author":"FR Appelbaum","year":"1995","unstructured":"Appelbaum FR, Clift RA, Radich J, Anasetti C, Buckner CD. Bone marrow transplantation for chronic myelogenous leukemia. Semin Oncol 1995; 22:405\u2013411.","journal-title":"Semin Oncol"},{"issue":"l","key":"10_CR4","first-page":"72","volume":"8","author":"P Herve","year":"1991","unstructured":"Herve P, Labopin M, Plouvier E, Palut P, Tiberghien P, Gorin NC. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a European survey. EBMT Working Party on ABMT. Bone Marrow Transplant. 1991; 8 (Suppl l):72\u201375.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR5","first-page":"453","volume":"7","author":"K Doney","year":"1991","unstructured":"Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation: multivariate analysis of factors affecting acute graft-vs-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991;7:453\u2013459.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","volume":"124","author":"M Michallet","year":"1996","unstructured":"Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Int Med 1996; 124:311\u2013315.","journal-title":"Ann Int Med"},{"key":"10_CR7","first-page":"60","volume":"25","author":"IW Flinn","year":"1998","unstructured":"Flinn IW, Vogelsang G. Bone marrow transplantation for chronic lymphocytic leukemia. Semin Oncol 1998; 25:60\u201364.","journal-title":"Semin Oncol"},{"key":"10_CR8","first-page":"643","volume":"45","author":"T Witte De","year":"1997","unstructured":"De Witte T. Allogeneic and autologous stem cell transplantation in myelodysplastic syndromes. Pathologie Biologie 1997; 45:643\u2013649.","journal-title":"Pathologie Biologie"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.bmt.1701084","volume":"21","author":"V Runde","year":"1998","unstructured":"Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998; 21:255\u2013261.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1046\/j.1365-2141.1997.3083125.x","volume":"98","author":"JE Anderson","year":"1997","unstructured":"Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98:1010\u20131016.","journal-title":"Br J Haematol"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3322\/canjclin.48.1.6","volume":"48","author":"SH Landis","year":"1998","unstructured":"Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics: 1998. Ca: A Cancer Journal for Clinicians 1998; 48:6\u201329.","journal-title":"Ca: A Cancer Journal for Clinicians"},{"key":"10_CR12","unstructured":"National Board of Health and Welfare. The Cancer Registry. Cancer incidence in Sweden 2000. Statistics Health and Disease 2002; 5."},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91\u201397.","journal-title":"N Engl J Med"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, et al, for the Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875\u20131883.","journal-title":"N Engl J Med"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot, G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87:1196\u20131198.","journal-title":"Blood"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(05)64529-1","volume":"348","author":"LF Verdonck","year":"1996","unstructured":"Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen, EJ. Graft-versus-myeloma effect in two cases. Lancet 1996; 348:346.","journal-title":"Lancet"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","volume":"348","author":"J Aschan","year":"1996","unstructured":"Aschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton, G. Graft-versus-myeloma effect. Lancet 1996; 348:346.","journal-title":"Lancet"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJM198306093082319","volume":"308","author":"N Sadamori","year":"1983","unstructured":"Sadamori N, Ozer H, Higby DJ, Sandberg AA. Chromosomal evidence of donor B-lympho-cyte engraftment after bone-marrow transplantation in a patient with multiple myeloma. N Engl J Med 1983; 308:1423\u20131424.","journal-title":"N Engl J Med"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1600-0609.1986.tb00824.x","volume":"36","author":"S Tura","year":"1986","unstructured":"Tura S, Cavo M, Baccarani M, Ricci P, Gobbi M. Bone marrow transplantation in multiple myeloma. Scand. J Haematol. 1986; 36:176\u2013179.","journal-title":"Scand. J Haematol"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.0954-6820.1986.tb03350.x","volume":"219","author":"G Gahrton","year":"1986","unstructured":"Gahrton G, Ringden O, Lonnqvist B, Lindquist R, Ljungman P. Bone marrow transplantation in three patients with multiple myeloma. Acta Med Scand. 1986; 219:523\u2013527.","journal-title":"Acta Med Scand"},{"key":"10_CR21","first-page":"823","volume":"292","author":"ED Thomas","year":"1975","unstructured":"Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975; 292:823\u2013843.","journal-title":"N Engl J Med"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood.V89.7.2610","volume":"89","author":"N Russell","year":"1997","unstructured":"Russell N, Miflin G, Stainer C, et al. Allogeneic bone marrow transplant for multiple myeloma. Blood 1997; 89:2610\u20132617.","journal-title":"Blood"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","volume":"325","author":"G Gahrton","year":"1991","unstructured":"Gahrton G, Tura S, Ljungman P, et al, for the European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991; 325:1267\u20131273.","journal-title":"N Engl J Med"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","volume":"13","author":"G Gahrton","year":"1995","unstructured":"Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13:1312\u20131322.","journal-title":"J Clin Oncol"},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.1992.10.9.1492","volume":"10","author":"WI Bensinger","year":"1992","unstructured":"Bensinger WI, Buckner CD, Clift RA, et al. A phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10:1492\u20131497.","journal-title":"J Clin Oncol"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","volume":"88","author":"WI Bensinger","year":"1996","unstructured":"Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88:2787\u20132793.","journal-title":"Blood"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.bmt.1701280","volume":"22","author":"M Cavo","year":"1998","unstructured":"Cavo, M, Bandini, G, Benni, M, et al. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant. 1998; 22:27\u201332.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91:756\u2013763.","journal-title":"Blood"},{"issue":"5","key":"10_CR29","first-page":"78","volume":"27","author":"BM Sandmaier","year":"2000","unstructured":"Sandmaier BM, McSweeney P, Yu C, Storb R. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol. 2000; 27(2 Suppl 5):78\u201381.","journal-title":"Semin Oncol"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/bbmt.2001.v7.pm11669218","volume":"7","author":"JM Zaucha","year":"2001","unstructured":"Zaucha JM, Yu C, Zellmer E, et al. Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. Biol Blood Marrow Transplant 2001; 7:513\u2013516.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10_CR31","first-page":"222","volume":"4","author":"P Corradini","year":"2003","unstructured":"Corradini P, Montefusco V, Rizzo E, et al. Myeloablative versus reduced-intensity conditioning followed by allogeneic stem cell transplantation in multiple myeloma patients [abstract]. Hematol J 2003; 4 (Suppl 1):S222. Abstract 301.","journal-title":"Hematol J"},{"issue":"9","key":"10_CR32","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102:9:3447\u20133454.","journal-title":"Blood"},{"issue":"1","key":"10_CR33","first-page":"224","volume":"4","author":"C Crawley","year":"2003","unstructured":"Crawley C, Szydlo R, Lalancette M, et al. Results of Reduced intensity conditioning allogeneic transplantation in Myeloma: a report from EBMT [abstract]. Hematol J 2003; 4(Suppl 1): S224. Abstract 305.","journal-title":"Hematol J"},{"issue":"1","key":"10_CR34","first-page":"225","volume":"4","author":"A Carrasco","year":"2003","unstructured":"Carrasco A, Aleman A, de Lima M, et al. Outcomes in patients with refractory relapse multiple myeloma after reduced intensity conditioning regimen allograft or myeloablative autologous stem cell transplantation [abstract]. Hematol J 2003; 4(Suppl 1):S225. Abstract 306.","journal-title":"Hematol J"},{"issue":"1","key":"10_CR35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.thj.6200213","volume":"4","author":"H Einsele","year":"2003","unstructured":"Einsele H, Schaefer HJ, Bader P, et al. Followup of patients with progressive MM undergoing allografts after reduced intensity conditioning [abstract]. Hematol J 2003; 4(Suppl 1):S225. Abstract 307.","journal-title":"Hematol J"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003; 102:3447\u20133454.","journal-title":"Blood"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","volume":"121","author":"H Einsele","year":"2003","unstructured":"Einsele H, Schafer HJ, Hebart H, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121:411\u2013418.","journal-title":"Br J Haematol"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","volume":"9","author":"KS Peggs","year":"2003","unstructured":"Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9:257\u2013265.","journal-title":"Biol Blood Marrow Transplant"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","volume":"30","author":"S Giralt","year":"2002","unstructured":"Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002; 30:367\u2013373.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","volume":"31","author":"CK Lee","year":"2003","unstructured":"Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003;31:73\u201380.","journal-title":"Exp Hematol"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","volume":"100","author":"N Kroger","year":"2002","unstructured":"Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002; 100:755\u2013760.","journal-title":"Blood"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","volume":"100","author":"N Kroger","year":"2002","unstructured":"Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002; 100:3919\u20133924.","journal-title":"Blood"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood.V98.4.934","volume":"98","author":"E Alyea","year":"2001","unstructured":"Alyea E, Weller E, Schlossman R, et al. T cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft versus myeloma effect. Blood. 2001; 98:934\u2013939.","journal-title":"Blood"},{"key":"10_CR44","doi-asserted-by":"crossref","unstructured":"Alyea E, Weller E, Schlossman R, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft versus myeloma effect. Biol Blood Bone Marrow Transpl 2003. In press.","DOI":"10.1038\/sj.bmt.1704289"},{"issue":"1","key":"10_CR45","first-page":"S39","volume":"27","author":"PCM Corradini","year":"2001","unstructured":"Corradini PCM, Lokhorst H, Martinelli G, et al. Molecular remissions are frequently achieved in myeloma patients undergoing allografting with peripheral blood stem cells. Bone Marrow Transplantation. 2001; 27(Suppl 1):S39.","journal-title":"Bone Marrow Transplantation"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation (annotation). Br J Haematol 1998; 102:1115\u20131123.","journal-title":"Br J Haematol"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","volume":"113","author":"G Gahrton","year":"2001","unstructured":"Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001; 113:209\u2013216.","journal-title":"Br J Haematol"},{"issue":"2","key":"10_CR48","first-page":"620","volume":"93","author":"RG Owen","year":"1996","unstructured":"Owen RG, Bybee A, Cooke F, et al. Minimal residual disease after allogeneic and autologous stem cell transplant in myeloma. Br J Haematol 1996; 93(Suppl 2): no. 620.","journal-title":"Br J Haematol"},{"key":"10_CR49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","volume":"17","author":"P Corradini","year":"1999","unstructured":"Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17:208\u2013215.","journal-title":"J Clin Oncol"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","volume":"102","author":"P Corradini","year":"2003","unstructured":"Corradini P, Cavo M, Lokhorst, H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in multiple myeloma. Blood 2003; 102:1927\u20131929.","journal-title":"Blood"},{"key":"10_CR51","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","volume":"90","author":"HM Lokhorst","year":"1997","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90:4206\u20134211.","journal-title":"Blood"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1083-8791(00)70014-0","volume":"6","author":"E Orsini","year":"2000","unstructured":"Orsini E, Alyea EP, Chillemi A, et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transpl. 2000; 6:375\u2013386.","journal-title":"Biol Blood Marrow Transpl"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/sj.bmt.1702187","volume":"25","author":"E Orsini","year":"2000","unstructured":"Orsini E, Alyea E., Schlossman R, et al. Changes in T cell receptor repertoire associated with graft-versus tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma receiving donor lymphocyte infusion. Bone Marrow Transpl. 2000; 25:623\u2013632.","journal-title":"Bone Marrow Transpl"},{"key":"10_CR54","first-page":"2561","volume":"63","author":"E Orsini","year":"2003","unstructured":"Orsini E, Bellucci R, Alyea EP, et al. Expansion of tumor specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003; 63:2561\u20132568.","journal-title":"Cancer Res."},{"issue":"2","key":"10_CR55","first-page":"122","volume":"13","author":"G Gahrton","year":"1995","unstructured":"Gahrton G, Tura S, Ljungman P, et al, for the European Group for Blood and Marrow Transplantation. An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. Stem Cells 1995; 13(Suppl 2): 122\u2013125.","journal-title":"Stem Cells"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0889-8588(05)70420-2","volume":"11","author":"WI Bensinger","year":"1997","unstructured":"Bensinger WI, Buckner CD, Gahrton G. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin N Am 1997; 11:147\u2013157.","journal-title":"Hematol Oncol Clin N Am"},{"key":"10_CR57","first-page":"117","volume":"15","author":"DE Reece","year":"1995","unstructured":"Reece DE, Shepherd JD, Klingemann HG, et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:117\u2013123.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR58","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood.V81.5.1404a.1404a","volume":"81","author":"P Dreger","year":"1993","unstructured":"Dreger P, Suttorp M, Haferlach T, Loffler H, Schmitz N, Schroyens W. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81:1404\u20131407.","journal-title":"Blood"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/sj.bmt.1701234","volume":"21","author":"N Schmitz","year":"1998","unstructured":"Schmitz, N, Bacigalupo, A, Hasenclever D, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilized peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21:995\u20131003.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR60","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/blood.V88.7.2794.bloodjournal8872794","volume":"88","author":"WI Bensinger","year":"1996","unstructured":"Bensinger, WI, Clift, RA, Martin, P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88:2794\u20132800.","journal-title":"Blood"},{"key":"10_CR61","first-page":"683","volume":"82","author":"A Urbano-Ispizua","year":"1997","unstructured":"Urbano-Ispizua A, Garcia-Conde J, Brunet S, et al. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT. Haematologica 1997; 82:683\u2013669.","journal-title":"Haematologica"},{"key":"10_CR62","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood.V90.12.4705","volume":"90","author":"J Storek","year":"1997","unstructured":"Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90:4705\u20134709.","journal-title":"Blood"},{"key":"10_CR63","first-page":"213","volume-title":"Allogeneic transplantation with bone marrow or peripheral blood stem cells for multiple myeloma: a multivariate analysis of risk factors on outcome. Molecular and clinical remissions in multiple myeloma: the role of auto\/allografting of hematopoietic cells","author":"M Cavo","year":"1998","unstructured":"Cavo M, Bandini G, Lemoli RM, et al. Allogeneic transplantation with bone marrow or peripheral blood stem cells for multiple myeloma: a multivariate analysis of risk factors on outcome. Molecular and clinical remissions in multiple myeloma: the role of auto\/allografting of hematopoietic cells. Abstract presented at: 24th Annual Meeting European Group for Blood and Marrow Transplantation; Courmayeur, Italy; March 22\u201326, 1998. Abstract No. 746, p. S213."},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/sj.bmt.1703924","volume":"31","author":"I Majolino","year":"2003","unstructured":"Majolino I, Corradini P, Scime R, et al. High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplant 2003; 31:767\u2013773.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR65","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","volume":"88","author":"B Bjorkstrand","year":"1996","unstructured":"Bjorkstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88:4711\u20134718.","journal-title":"Blood"},{"key":"10_CR66","first-page":"1269","volume":"76","author":"A Fefer","year":"1986","unstructured":"Fefer A, Cheever MA, Greenberg PD. Identical-twin (syngeneic) marrow transplantation for hematologic cancer. J Natl Cancer Inst 1986; 76:1269\u20131273.","journal-title":"J Natl Cancer Inst"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000206984","volume":"68","author":"ED Osserman","year":"1982","unstructured":"Osserman ED, Dire LB, Sherman WH, Hersman JA, Storb R. Identical twin marrow transplantation in multiple myeloma. Acta Haematologica 1982; 68,215\u2013223.","journal-title":"Acta Haematologica"},{"key":"10_CR68","first-page":"527","volume":"18","author":"WI Bensinger","year":"1996","unstructured":"Bensinger WI, Demierer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996; 18:527\u2013531.","journal-title":"Bone Marrow Transplant"},{"key":"10_CR69","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/sj.bmt.1701975","volume":"24","author":"G Gahrton","year":"1999","unstructured":"Gahrton G, Svensson H, Bjorkstrand B, et al. Syngeneic transplantation in multiple myeloma: a case-matched comparison with autologous and allogeneic transplantation. Bone Marrow Transplant 1999; 24:741\u2013745.","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology and Management of Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-59259-817-5_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:56:19Z","timestamp":1595897779000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-59259-817-5_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"ISBN":["9781617371431","9781592598175"],"references-count":69,"URL":"https:\/\/doi.org\/10.1007\/978-1-59259-817-5_10","relation":{},"subject":[],"published":{"date-parts":[[2004]]}}}